LDLR and prostate carcinoma: It has been widely acknowledged that the expression of cell surface low-density lipoprotein receptors (LDLR) is usually upregulated in many cancer cell lines, including breast carcinoma, prostate carcinoma, and HCC (Liang et al., 2017).